racecadotril (ecadotril)

parenterally active enkephalinase inhibitor

Also Known As:

ecadotril; N-(3-acetylmercapto-2-benzylpropanoyl)glycine benzyl ester; acetorphan; acetorphan, (R)-isomer; acetorphan, (S)-isomer; retorphan; sinorphan; Glycine, N-(2-((acetylthio)methyl)-1-oxo-3-phenylpropyl)-, phenylmethyl ester, (+-)-

Networked: 90 relevant articles (18 outcomes, 28 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rautenberg, Tamlyn Anne: 4 articles (01/2022 - 01/2012)
2.	Eberlin, Marion: 3 articles (01/2018 - 01/2012)
3.	Zerwes, Ute: 3 articles (01/2018 - 01/2012)
4.	Mueck, Tobias: 2 articles (01/2018 - 01/2016)
5.	Andresen, Viola: 2 articles (09/2016 - 01/2016)
6.	Layer, Peter: 2 articles (09/2016 - 01/2016)
7.	Guarino, Alfredo: 2 articles (01/2012 - 04/2009)
8.	Santos, Mar: 2 articles (09/2011 - 07/2009)
9.	Salazar-Lindo, E: 2 articles (05/2005 - 08/2000)
10.	Goetze, L: 2 articles (06/2000 - 04/2000)

Related Diseases

1.	Diarrhea 09/01/2013 - "Racecadotril has sufficient proven efficacy in the treatment of acute diarrhea in children. " 04/01/2009 - "Racecadotril showed a potent and selective inhibition of active secretion, being particularly effective in the first phase of RV diarrhea. " 05/06/2016 - "Is racecadotril effective for acute diarrhea in children? " 01/01/2012 - "In contrast, racecadotril was consistently effective in animal models and patients with various forms of acute diarrhea by inhibiting pathologic (but not basal) secretion from the gut without changing gastro-intestinal transit time or motility. " 08/17/2000 - "In young boys with acute watery diarrhea, racecadotril is an effective and safe treatment."
2.	Heart Failure 12/01/1999 - "A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. " 06/01/2000 - "Intrarenal effects of ecadotril during acute volume expansion in dogs with congestive heart failure." 03/01/2000 - "To evaluate short-term hemodynamic effects of ecadotril in a model of congestive heart failure in dogs. " 03/01/2000 - "Short-term effects of ecadotril in dogs with induced congestive heart failure." 12/01/1999 - "In this small pilot study, ecadotril in doses of 50 to 400 mg twice daily was generally well-tolerated and without severe short-term adverse effects in patients with mild to moderate heart failure. "
3.	Abdominal Pain (Pain, Abdominal) 01/01/1995 - "During the control period, 3 out of 15 patients did not have significant diarrhoea, but 2 out of 3 patients had abdominal pain which was relieved by acetorphan without appearance of constipation. " 06/01/2002 - "Racecadotril produced a significantly greater reduction in abdominal pain and distension than loperamide (P = 0.024 and 0.03, respectively). " 02/01/2010 - "In the per-protocol (PP) population, the median time of abdominal pain was 14 h for racecadotril and 32 h for loperamide (P < 0.01). " 02/01/2010 - "The median time of abdominal pain in the intent-to-treat (ITT) population was 14 h for racecadotril and 28 h for loperamide. " 06/01/1992 - "The significant antidiarrhoeal activity of acetorphan was established using a variety of criteria: (i) the duration of both diarrhoea and treatment were diminished; (ii) no acetorphan treated patient withdrew from the study whereas five dropped out because of worsening in the placebo group; (iii) the frequency of symptoms associated with diarrhoea--for example, abdominal pain or distension, nausea and anorexia--remaining after two weeks was nearly halved; (iv) using visual analogue scales acetorphan treatment was found more effective than placebo by both investigators and patients. "
4.	Gastroenteritis 01/01/2017 - "The objectives of this study were: to compare the number of stools in the first 48 hours in children with severe gastroenteritis requiring admission and treated with either racecadotril or placebo, to study the impact of racecadotril on duration of inpatient stay as well as duration of diarrhoea and to describe the side effect profile of racecadotril. " 07/01/2009 - "Use of racecadotril as outpatient treatment for acute gastroenteritis: a prospective, randomized, parallel study." 09/15/2007 - "The small number of included trials provided some evidence in favour of the use of racecadotril over placebo or no intervention, to reduce the stool output and duration of diarrhoea in children with acute gastroenteritis. " 09/15/2007 - "To summarize studies testing the efficacy and safety of racecadotril for treating children with acute gastroenteritis. " 09/01/2011 - "Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis."
5.	Constipation 06/01/2002 - "The duration of abdominal distension was significantly shorter with racecadotril (5.4 versus 24.4 h; P = 0.0001), and constipation was also significantly less frequent (16% versus 25%; P = 0.001). " 01/01/1995 - "During the control period, 3 out of 15 patients did not have significant diarrhoea, but 2 out of 3 patients had abdominal pain which was relieved by acetorphan without appearance of constipation. " 01/01/2016 - "In six randomized studies in outpatients comparing racecadotril to loperamide, resolution of symptoms occurred with similar speed and efficacy; however, racecadotril treatment was associated with less rebound constipation and less abdominal discomfort. " 01/01/2012 - "In direct comparative studies with loperamide in adults and children, racecadotril was at least as effective but exhibited fewer adverse events in most studies, particularly less rebound constipation. " 06/01/2002 - "Racecadotril resolved the symptoms of acute diarrhoea rapidly and effectively, and produced more rapid resolution of abdominal symptoms and less constipation than loperamide."

Related Drugs and Biologics

1.	Loperamide (Imodium)
2.	Neprilysin (Neutral Endopeptidase)
3.	racecadotril (ecadotril)
4.	Zinc
5.	Octreotide (Sandostatin)
6.	Smectite
7.	Diuretics
8.	Antidiarrheals
9.	Solutions
10.	Atrial Natriuretic Factor (ANF)

Related Therapies and Procedures

1.	Fluid Therapy (Oral Rehydration Therapy)
2.	Therapeutics
3.	Oral Administration
4.	Length of Stay